Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with epithelial ovarian cancer (including fallopian tube or primary peritoneal cancer) or endometrial cancer, confirmed by a tissue or cell sample test
• People whose cancer has come back more than 6 months after their last platinum-based chemotherapy treatment (called "platinum-sensitive" recurrence), with evidence of this return shown on scans
• Women aged 18 or older
• People who are in good general health, able to carry out daily activities with little or no difficulty (as measured by a standard health scale called WHO performance status 0–1), whose health has not declined in the past 2 weeks, and who are expected to live at least 12 weeks
• People who have at least one area of cancer that can be measured or tracked on CT or PET/CT scans
• People whose blood counts are at acceptable levels without needing a blood transfusion or medication to boost blood cell production in the 2 weeks before starting the study — including haemoglobin, white blood cell counts, and platelet levels meeting specific thresholds (confirm with trial site)
• People whose liver, kidney, and overall organ function meet the required levels, including liver enzyme levels, bilirubin, blood protein (albumin), and kidney filtering ability (confirm with trial site)
• Women who could potentially become pregnant must agree to use reliable contraception before joining, throughout the trial, and for 6 months after treatment ends — this includes any woman who has not had a hysterectomy or removal of both ovaries, or who has not gone through menopause for at least 12 consecutive months
• People who are willing and able to understand and sign a written consent form

Who may not be able to join:

• People who have received another experimental drug or taken part in a clinical trial within 28 days (or 5 half-lives of that drug, whichever is longer) before the first dose
• People who have had any other chemotherapy, immunotherapy, or cancer treatment within 14 days before the first dose
• People who have had major surgery (not including insertion of a vascular access line) within 4 weeks before the first dose
• People who have had wide-field radiation therapy within 4 weeks, or limited palliative radiation within 2 weeks, before the first dose
• People who still have significant side effects from previous cancer treatments (above a minor level), except for hair loss
• People with severe or uncontrolled health conditions, including active bleeding disorders, uncontrolled infections, or active hepatitis B, hepatitis C, or HIV
• People with a known severe allergic reaction (grade 3 or higher) to sacituzumab govitecan (SG) or cisplatin, or any of their ingredients
• People with nerve damage in the hands or feet rated at grade 2 or above (causing noticeable symptoms)
• People with ongoing severe nausea and vomiting, or chronic digestive system diseases
• People who are pregnant or breastfeeding
• Women who could potentially become pregnant and are unwilling to use effective contraception during the trial and for 6 months after treatment ends
• People who have had unstable chest pain (angina), a heart attack, or heart failure within the past 6 months, or who have a significant heart rhythm problem requiring medication (stable atrial fibrillation is generally acceptable — confirm with trial site)
• People with a significant active lung condition such as severe COPD or another moderate-to-severe chronic breathing illness present within the past 6 months
• People who have had a significant bleeding episode, a bowel blockage, or a hole in the digestive tract within the past 6 months
• People with other medical or mental health conditions that, in the trial doctor's opinion, could affect the trial results or prevent them from completing the trial
• People who have previously been treated with sacituzumab govitecan, irinotecan, or certain similar antibody-based drug treatments at any time
• People with active inflammatory bowel disease (such as ulcerative colitis or Crohn's disease), or a hole in the digestive tract within the past 6 months
• People who need to continue taking any medications that are not permitted during the trial
• People with active cancer that has spread to the brain or the lining around the brain — although people with previously treated and stable brain metastases for at least 4 weeks may be considered (confirm with trial site); anyone with cancer in the membrane around the brain is excluded regardless
• People who currently have another active cancer — although people who have been cancer-free for 3 or more years, or who have had certain low-risk cancers fully removed, may be considered (confirm with trial site)
• People who have received a live vaccine within 30 days before the first dose
• People who have a serious active infection currently requiring antibiotic, antiviral, or antifungal treatment

Important: Always verify eligibility with the trial site directly before applying.